Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kazia Therapeutics Limited

1.18
+0.334939.63%
Post-market: 1.11-0.0697-5.91%19:59 EST
Volume:4.50M
Turnover:5.61M
Market Cap:6.60M
PE:-0.17
High:1.44
Open:0.8107
Low:0.8000
Close:0.8451
Loading ...

Company Profile

Company Name:
Kazia Therapeutics Limited
Exchange:
NASDAQ
Establishment Date:
1994
Employees:
- -
Office Location:
Three International Towers,Level 24,300 Barangaroo Avenue,Sydney,New South Wales,Australia
Zip Code:
2000
Fax:
- -
Introduction:
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.

Directors

Name
Position
John Friend
Chief Executive Officer and Interim Chairman
Bryce Carmine
Non-Executive Director
Ebru Davidson
Non-Executive Director
Steven Coffey
Non-Executive Director

Shareholders

Name
Position
John Friend
Chief Executive Officer and Interim Chairman
Karen Krumeich
Chief Financial Officer
Anna Sandham
Company Secretary